Georgia's Online Cancer Information Center

Bile Duct Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Bile Duct Cancer
Cancer Type = Bile Duct Cancer
There are currently 14 active Bile Duct Cancer clinical trials in Georgia.
1.
NCORP Trial
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type
Bile Duct Cancer, Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gynecologic Cancers, Head and Neck Cancer, Hematopoietic Malignancies, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Primary Peritoneal Cancer, Stomach/ Gastric Cancer
NCT ID
NCT03329950
Protocol IDs
CDX1140-01
NCI-2018-00959
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
2.
A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)
Cancer Type
Bile Duct Cancer, Breast Cancer, Gallbladder Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Neuroendocrine Tumor, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT04105335
Protocol IDs
MNA-3521-012
NCI-2021-05987
2019-002231-28
3.
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
Cancer Type
Bile Duct Cancer, Gallbladder Cancer
NCT ID
NCT04466891
Protocol IDs
ZWI-ZW25-203
NCI-2020-06114
2020-000459-11
4.
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Cancer Type
Bile Duct Cancer
NCT ID
NCT03656536
Protocol IDs
INCB 54828-302
NCI-2019-01725
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
Cancer Type
Bile Duct Cancer, Gynecologic Cancers, Ovarian Cancer, Prostate Cancer
NCT ID
NCT04972981
Protocol IDs
ADCT-901-101
NCI-2021-10797
2021-002292-19
6.
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Cancer Type
Bile Duct Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Stomach/ Gastric Cancer
NCT ID
NCT04396821
Protocol IDs
TST001-1001
NCI-2020-05881
7.
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Cancer Type
Bile Duct Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Neuroendocrine Tumor, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCT ID
NCT02568267
Protocol IDs
RXDX-101-02
NCI-2015-01848
Treatment Sites (2)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
Gemcitabine and Cisplatin with Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Cancer Type
Bile Duct Cancer
NCT ID
NCT04088188
Protocol IDs
ACCRU-ICRN-1701
NCI-2019-05811
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
Niraparib and Dostarlimab for the Treatment of Advanced Cholangiocarcinoma
Cancer Type
Bile Duct Cancer
NCT ID
NCT04895046
Protocol IDs
HCRN-GI19-414
NCI-2021-01326
10.
NCORP Trial
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type
Adrenal Cancer, Bile Duct Cancer, Bladder Cancer, Bone Tumor, Brain Tumor, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Germ Cell Tumor, Gestational trophoblastic disease, Gynecologic Cancers, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Mesothelioma, Neuroendocrine Tumor, Ovarian Cancer, Parathyroid Cancer, Penile Cancer, Retroperitoneal Tumors, Sarcoma, Small Bowel Cancer, Solid Tumor, Stomach/ Gastric Cancer, Testicular Cancer, Thyroid Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT02834013
Protocol IDs
S1609
NCI-2016-01041
Treatment Sites (10)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Piedmont Fayette Hospital
Fayetteville
404-851-2340
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
Olaparib in Treating Patients with Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations
Cancer Type
Bile Duct Cancer, Brain & Spinal Cord Tumor
NCT ID
NCT03212274
Protocol IDs
10129
10129
NCI-2017-01182
2000023083
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
Pembrolizumab and Hsp90 inhibitor XL888 in Treating Patients with Advanced Gastrointestinal Cancer
Cancer Type
Bile Duct Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Pancreatic Cancer, Small Bowel Cancer, Stomach/ Gastric Cancer
NCT ID
NCT03095781
Protocol IDs
Winship3321-16
NCI-2016-01594
IRB00087397
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Cancer Type
Bile Duct Cancer
NCT ID
NCT03773302
Protocol IDs
QBGJ398-301
NCI-2019-01025
2018-004004-19
Treatment Sites (4)
Piedmont Cancer Institute - Atlanta
Atlanta
Katie Adams
678-298-3238
Piedmont Cancer Institute - Fayetteville
Fayetteville
678-298-3238
Piedmont Cancer Institute - Newnan
Newnan
Katie Adams
678-298-3238
Piedmont Cancer Institute - Stockbridge
Stockbridge
Katie Adams
678-298-3238
14.
TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Cancer Type
Bile Duct Cancer
NCT ID
NCT03368963
Protocol IDs
Winship4146-17
NCI-2017-01661
IRB00098958
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.